Evaluation of a self-questionnaire to screen for neurological complications associated with immunological checkpoint inhibitors: Are we missing something?

Lemarchant, B; Mortier, L; Lannoy, J; Dubucquoi, S; Zephir, H

Lemarchant, B; Mortier, L; Lannoy, J; Dubucquoi, S; Zephir, H.

Afiliação

Lemarchant B; Unité de neurologie inflammatoire, CRC-SEP, Department of Neurology, CHU de Lille, hôpital Roger-Salengro, Lille, France; Inserm U1172, université de Lille, Lille, France. Electronic address: bruno.lemarchant@chu-lille.fr.
Mortier L; Department of Dermatology, CHU de Lille, hôpital Huriez, Lille, France; Inserm U1189, université de Lille, Lille, France.
Lannoy J; Department of Neurology, centre hospitalier Lens, Lens, France.
Dubucquoi S; Inserm, U1286-INFINITE: Institute for Translational Research in Inflammation, CHU de Lille, université de Lille, Lille, France.
Zephir H; Unité de neurologie inflammatoire, CRC-SEP, Department of Neurology, CHU de Lille, hôpital Roger-Salengro, Lille, France; Inserm U1172, université de Lille, Lille, France.

Rev Neurol (Paris) ; 179(10): 1095-1102, 2023 Dec.

Article em En | MEDLINE | ID: mdl-37714728

Assuntos

Antineoplásicos Imunológicos; Neoplasias; Humanos; Antineoplásicos Imunológicos/efeitos adversos; Neoplasias/complicações; Neoplasias/tratamento farmacológico; Inquéritos e Questionários; Estudos Retrospectivos

Palavras-chave

Immune checkpoint inhibitors; Immune-related adverse events; Management; Neurological disorders; Neurotoxicity; Screening questionnaire

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antineoplásicos Imunológicos / Neoplasias Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google